Zeo ScientifiX, Inc. 8-K

What Happened
Zeo ScientifiX (ZEOX) filed a Form 8-K reporting that, effective January 23, 2026, it appointed Dr. John D. Kisiday, Ph.D., as Chief Science Officer. Dr. Kisiday brings nearly 30 years of experience in tissue engineering, regenerative medicine and orthobiologics, including faculty roles at Colorado State University and an adjunct professorship at the University of Wyoming. The company entered into an employment agreement with him the same day.

Key Details

• Base salary: $175,000 per year under the employment agreement (effective Jan 23, 2026).
• Equity: one-time stock grant of 50,000 common shares under the 2021 Incentive Plan; vesting is 20,000 shares on the 1st anniversary and 30,000 shares on the 2nd anniversary, contingent on continued employment.
• Severance: if terminated without Cause (after the first 90 days) or if Dr. Kisiday leaves for Good Reason, he is entitled to severance equal to 0.25 month’s salary for each completed three-month period of employment (per the agreement).
• Employment terms: at-will employment with customary confidentiality, non-competition and non-solicitation covenants; additional compensation may be payable if he brings a commercially viable new product or business opportunity outside ZEO’s current line of business.

Why It Matters
This is an executive hire focused on strengthening ZEOX’s scientific and product-development leadership in tissue engineering and orthobiologics. For investors, the appointment signals a company investment in R&D and potential pipeline expansion; the compensation package is modest in cash with performance-tied equity, aligning incentives to continued service and potential commercial contributions. The employment agreement’s at-will nature and limited severance reduce long-term financial commitment risk for the company.